1 Study Coverage
1.1 Cardiovascular Disease Drugs Product Introduction
1.2 Market Segments
1.3 Key Cardiovascular Disease Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Type
1.4.2 Heparin
1.4.3 Coumadin
1.4.4 Sectral
1.4.5 Zebeta
1.4.6 Lopressor
1.4.7 Toprol XL
1.4.8 Norvasc
1.4.9 Lotrel
1.4.10 Others
1.5 Market by Application
1.5.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Application
1.5.2 Asischemic Heart Disease
1.5.3 Dyslipidemia
1.5.4 Stroke
1.5.5 Thrombosis
1.5.6 Atherosclerosis
1.5.7 Coronary Artery Diseases
1.5.8 Peripheral Artery Disease
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Disease Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cardiovascular Disease Drugs Revenue 2015-2026
2.1.2 Global Cardiovascular Disease Drugs Sales 2015-2026
2.2 Global Cardiovascular Disease Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cardiovascular Disease Drugs Competitor Landscape by Players
3.1 Cardiovascular Disease Drugs Sales by Manufacturers
3.1.1 Cardiovascular Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Cardiovascular Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Cardiovascular Disease Drugs Revenue by Manufacturers
3.2.1 Cardiovascular Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Cardiovascular Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cardiovascular Disease Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cardiovascular Disease Drugs Revenue in 2019
3.2.5 Global Cardiovascular Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cardiovascular Disease Drugs Price by Manufacturers
3.4 Cardiovascular Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cardiovascular Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cardiovascular Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cardiovascular Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cardiovascular Disease Drugs Market Size by Type (2015-2020)
4.1.1 Global Cardiovascular Disease Drugs Sales by Type (2015-2020)
4.1.2 Global Cardiovascular Disease Drugs Revenue by Type (2015-2020)
4.1.3 Cardiovascular Disease Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cardiovascular Disease Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Cardiovascular Disease Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cardiovascular Disease Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cardiovascular Disease Drugs Market Size by Application (2015-2020)
5.1.1 Global Cardiovascular Disease Drugs Sales by Application (2015-2020)
5.1.2 Global Cardiovascular Disease Drugs Revenue by Application (2015-2020)
5.1.3 Cardiovascular Disease Drugs Price by Application (2015-2020)
5.2 Cardiovascular Disease Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Cardiovascular Disease Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cardiovascular Disease Drugs by Country
6.1.1 North America Cardiovascular Disease Drugs Sales by Country
6.1.2 North America Cardiovascular Disease Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cardiovascular Disease Drugs Market Facts & Figures by Type
6.3 North America Cardiovascular Disease Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Cardiovascular Disease Drugs by Country
7.1.1 Europe Cardiovascular Disease Drugs Sales by Country
7.1.2 Europe Cardiovascular Disease Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cardiovascular Disease Drugs Market Facts & Figures by Type
7.3 Europe Cardiovascular Disease Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cardiovascular Disease Drugs by Region
8.1.1 Asia Pacific Cardiovascular Disease Drugs Sales by Region
8.1.2 Asia Pacific Cardiovascular Disease Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Type
8.3 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cardiovascular Disease Drugs by Country
9.1.1 Latin America Cardiovascular Disease Drugs Sales by Country
9.1.2 Latin America Cardiovascular Disease Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Type
9.3 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cardiovascular Disease Drugs by Country
10.1.1 Middle East and Africa Cardiovascular Disease Drugs Sales by Country
10.1.2 Middle East and Africa Cardiovascular Disease Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Johnson&Johnson
11.2.1 Johnson&Johnson Corporation Information
11.2.2 Johnson&Johnson Description and Business Overview
11.2.3 Johnson&Johnson Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Johnson&Johnson Cardiovascular Disease Drugs Products Offered
11.2.5 Johnson&Johnson Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Cardiovascular Disease Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Description and Business Overview
11.4.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sanofi Cardiovascular Disease Drugs Products Offered
11.4.5 Sanofi Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Cardiovascular Disease Drugs Products Offered
11.5.5 Merck Related Developments
11.6 Daiichi Sankyo Company Limited
11.6.1 Daiichi Sankyo Company Limited Corporation Information
11.6.2 Daiichi Sankyo Company Limited Description and Business Overview
11.6.3 Daiichi Sankyo Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Products Offered
11.6.5 Daiichi Sankyo Company Limited Related Developments
11.7 Novartis
11.7.1 Novartis Corporation Information
11.7.2 Novartis Description and Business Overview
11.7.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Novartis Cardiovascular Disease Drugs Products Offered
11.7.5 Novartis Related Developments
11.8 Bayer
11.8.1 Bayer Corporation Information
11.8.2 Bayer Description and Business Overview
11.8.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Bayer Cardiovascular Disease Drugs Products Offered
11.8.5 Bayer Related Developments
11.9 Takeda Pharmaceutical
11.9.1 Takeda Pharmaceutical Corporation Information
11.9.2 Takeda Pharmaceutical Description and Business Overview
11.9.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Products Offered
11.9.5 Takeda Pharmaceutical Related Developments
11.10 Hoffmann-La Roche
11.10.1 Hoffmann-La Roche Corporation Information
11.10.2 Hoffmann-La Roche Description and Business Overview
11.10.3 Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Hoffmann-La Roche Cardiovascular Disease Drugs Products Offered
11.10.5 Hoffmann-La Roche Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.12 Actelion Pharmaceuticals
11.12.1 Actelion Pharmaceuticals Corporation Information
11.12.2 Actelion Pharmaceuticals Description and Business Overview
11.12.3 Actelion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Actelion Pharmaceuticals Products Offered
11.12.5 Actelion Pharmaceuticals Related Developments
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Corporation Information
11.13.2 Boehringer Ingelheim Description and Business Overview
11.13.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Boehringer Ingelheim Products Offered
11.13.5 Boehringer Ingelheim Related Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Description and Business Overview
11.14.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Products Offered
11.14.5 Astellas Pharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cardiovascular Disease Drugs Market Estimates and Projections by Region
12.1.1 Global Cardiovascular Disease Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Cardiovascular Disease Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.2.2 North America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cardiovascular Disease Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cardiovascular Disease Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cardiovascular Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
【掲載企業】
AstraZeneca、Johnson&Johnson、Pfizer、Sanofi、Merck、Daiichi Sankyo Company Limited、Novartis、Bayer、Takeda Pharmaceutical、Hoffmann-La Roche、United Therapeutics Corporation、Actelion Pharmaceuticals、Boehringer Ingelheim、Astellas Pharma
【免責事項】
https://www.globalresearch.jp/disclaimer